<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02925624</url>
  </required_header>
  <id_info>
    <org_study_id>1949</org_study_id>
    <nct_id>NCT02925624</nct_id>
  </id_info>
  <brief_title>CLOSE to CURE Study</brief_title>
  <official_title>'CLOSE'-Guided Pulmonary Vein Isolation as Cure for Paroxysmal Atrial Fibrillation?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AZ Sint-Jan AV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Title: CLOSE-guided pulmonary vein isolation (PVI) as Cure for Paroxysmal Atrial Fibrillation&#xD;
      ('CLOSE to CURE' study)&#xD;
&#xD;
      Design: This is a prospective, observational, single-center, unblinded, clinical 3-year&#xD;
      study.&#xD;
&#xD;
      Background: In a population of paroxysmal atrial fibrillation (AF) 'CLOSE'-guided PVI, a new&#xD;
      approach to obtain single-procedure durable PVI, has been shown to virtually eliminate&#xD;
      recurrence of AF at 1 year follow-up with repetitive but discontinuous Holter monitoring.&#xD;
&#xD;
      Objectives: (1) To objectively compare atrial tachyarrhythmia (ATA) burden before and after&#xD;
      'CLOSE'-guided based PVI using continuous monitoring. (2) To assess ATA burden using&#xD;
      continuous monitoring up to 3 years after ablation. (3) To identify baseline structural and&#xD;
      electrical properties of the atria or procedural characteristics that predict 1-year and&#xD;
      3-year outcome.&#xD;
&#xD;
      Enrollment: Up to 100 subjects will be enrolled in this observational, prospective study.&#xD;
&#xD;
      Clinical Sites: 1 site.&#xD;
&#xD;
      Subject Population: Eligible patients are patients with paroxysmal high-burden AF who are&#xD;
      planned for a 'CLOSE'-guided PV isolation. At the time of procedural planning we will ask the&#xD;
      patient his/her consent for (1) implantation of a subcutaneous continuous loop recorder&#xD;
      (sCLR), (2) a concise electrophysiological study at the time of PVI, (3) a transthoracic&#xD;
      echocardiogram at the time of PVI and (4) collection of data during 3 years. Anti-arrhythmic&#xD;
      drug treatment (ADT) and oral anticoagulation (OAC) will be given according the updated 2012&#xD;
      European society of Cardiology (ESC) guidelines on AF (Camm et al, European Heart Journal&#xD;
      2012) and the 2012 Heart rhythm society (HRS)/European Heart Rhythm association/European&#xD;
      cardiac arrhythmic society Expert Consensus Statement on catheter and surgical ablation of&#xD;
      atrial fibrillation (Calkins et al, Heart Rhythm 2012).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial tachyarrhythmia (ATA) burden before and after 'CLOSE'-guided based PVI</measure>
    <time_frame>Continuous monitoring (24 hours loop recording)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Long-term evaluation of ATA burden after a single 'CLOSE' guided PVI procedure</measure>
    <time_frame>Continuous monitoring (24 hours loop recording)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluating PV re-connection at redo procedure assessed by Lasso catheter</measure>
    <time_frame>3 months to 3 years</time_frame>
    <description>Visual inspection of electrograms on the Lasso catheter will be performed to verify durable PV isolation or re-connection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluating progression of scarring at redo procedure assessed by voltage mapping</measure>
    <time_frame>3 months to 3 years</time_frame>
    <description>Point-by-point bipolar voltage mapping will be performed to quantify the amount of low voltage areas in the left atrium (LA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events related to ablation</measure>
    <time_frame>Baseline to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from stroke/transient ischemic attack (TIA)</measure>
    <time_frame>Baseline to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of CLOSE protocol ablation assessed by single-procedure freedom from documented atrial tachyarrhythmias (ATA)</measure>
    <time_frame>1 month to 3 years</time_frame>
    <description>ATA include fibrillation, tachycardia, or flutter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of CLOSE protocol ablation assessed by incidence of repeat ablation procedures</measure>
    <time_frame>1 month to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of CLOSE protocol ablation assessed by multiple-procedure freedom from ATA</measure>
    <time_frame>1 month to 3 years</time_frame>
    <description>ATA include fibrillation, tachycardia, or flutter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics and outcomes research assessed by quality of life using Short Form (SF-36v2) Health Survey</measure>
    <time_frame>Recruitment to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics and outcomes research assessed by quality of life using Symptomatic Questionnaire V3</measure>
    <time_frame>Recruitment to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics and outcomes research assessed by number of hospitalization</measure>
    <time_frame>Recruitment to 3 years</time_frame>
    <description>Includes total number of hospitalizations and unscheduled arrhythmia-related health care provider visits</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by height</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by weight</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by age</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by sex</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by congestive heart failure history</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by hypertension history</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by stroke/TIA/Thromboembolism history</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by vascular disease history</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by diabetes mellitus</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by left ventricle ejection fraction (LVEF)</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by structural heart disease</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by endurance measured by amount of training/cycling per week</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by history of implanted devices</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by LA diameter measured by echocardiography</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by LA volume measured by echocardiography</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinical characteristic assessed by cardiovascular medication history</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Procedure characteristic assessed by procedure time</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Procedure characteristic assessed by radiofrequency time</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Procedure characteristic assessed by fluoroscopy time</measure>
    <time_frame>At baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Electrophysiological characteristic assessed by voltage mapping of the LA</measure>
    <time_frame>At baseline</time_frame>
    <description>Point-by-point bipolar voltage mapping will be performed to quantify the amount of low voltage areas in the LA</description>
  </other_outcome>
  <other_outcome>
    <measure>Electrophysiological characteristic assessed by atrial refractoriness</measure>
    <time_frame>At baseline</time_frame>
    <description>This will be done by premature stimulation protocol</description>
  </other_outcome>
  <other_outcome>
    <measure>Electrophysiological characteristic assessed by conduction velocity</measure>
    <time_frame>At baseline</time_frame>
    <description>This will be done by premature stimulation protocol</description>
  </other_outcome>
  <other_outcome>
    <measure>Electrophysiological characteristic assessed by AF inducibility</measure>
    <time_frame>At baseline</time_frame>
    <description>This will be done by premature stimulation protocol</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>CLOSE guided PVI and insertable cardiac monitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary vein isolation</intervention_name>
    <arm_group_label>CLOSE guided PVI and insertable cardiac monitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with symptomatic paroxysmal AF (history of self-terminating AF within 7 days&#xD;
             or history of self-terminating AF with 1 or more cardioversions within 48 hours after&#xD;
             onset), meeting following criteria at the out-patient clinic:&#xD;
&#xD;
               -  patient has at least 3 AF episodes in the last 3 months prior to the visit&#xD;
&#xD;
               -  AF episodes are symptomatic, and patient is drug-resistant (at least one class IC&#xD;
                  or III), or drug-intolerant (palpitations, fatigue, dyspnea, cardiomyopathy,â€¦)&#xD;
&#xD;
               -  no advanced structural heart disease&#xD;
&#xD;
               -  patient has a CHA2DS2-VASc score of 0, 1, 2, 3 or 4&#xD;
&#xD;
          2. Signed Patient Informed Consent Form.&#xD;
&#xD;
          3. Age 18 years or older.&#xD;
&#xD;
          4. Able and willing to comply with all follow-up testing and requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Persistent atrial fibrillation (history of AF&gt;7days or history of cardioversion &gt; 48h&#xD;
             of AF)&#xD;
&#xD;
          2. Previous ablation for AF&#xD;
&#xD;
          3. LA antero-posterior diameter &gt; 50 mm (parasternal long axis view , PLAX)&#xD;
&#xD;
          4. LVEF &lt; 35% (ejection fraction)&#xD;
&#xD;
          5. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac&#xD;
             cause&#xD;
&#xD;
          6. Coronary artery bypass grafting (CABG) procedure within the last three months&#xD;
&#xD;
          7. Awaiting cardiac transplantation or other cardiac surgery&#xD;
&#xD;
          8. Documented left atrial thrombus on imaging&#xD;
&#xD;
          9. Diagnosed atrial myxoma&#xD;
&#xD;
         10. Women who are pregnant or breastfeeding&#xD;
&#xD;
         11. Acute illness or active systemic infection or sepsis&#xD;
&#xD;
         12. Unstable angina&#xD;
&#xD;
         13. Uncontrolled heart failure&#xD;
&#xD;
         14. Myocardial infarction within the previous two months&#xD;
&#xD;
         15. History of blood clotting or bleeding abnormalities&#xD;
&#xD;
         16. Contraindication to anticoagulation therapy (ie, heparin or warfarin)&#xD;
&#xD;
         17. Life expectancy less than 12 months&#xD;
&#xD;
         18. Enrollment in any other study evaluating another device or drug&#xD;
&#xD;
         19. Presence of intramural thrombus, tumor or other abnormality that precludes catheter&#xD;
             introduction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mattias Duytschaever, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, AZ Sint-Jan Hospital Bruges, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Sint-Jan Hospital</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 29, 2016</study_first_submitted>
  <study_first_submitted_qc>October 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Sint-Jan AV</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Mattias Duytschaever</investigator_full_name>
    <investigator_title>Professor Doctor</investigator_title>
  </responsible_party>
  <keyword>ablation index</keyword>
  <keyword>pulmonary vein isolation</keyword>
  <keyword>implantable loop recorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

